Are hypertriglyceridemia and low HDL causal factors in the development of insulin resistance? (Q38188133)

From Wikidata

scientific article published on 07 January 2014

Language	Label	Description	Also known as
English	Are hypertriglyceridemia and low HDL causal factors in the development of insulin resistance?	scientific article published on 07 January 2014

Statements

instance of

scholarly article

1 reference

stated in

Europe PubMed Central

PubMed publication ID

24529133

retrieved

30 August 2017

title

Are hypertriglyceridemia and low HDL causal factors in the development of insulin resistance? (English)

1 reference

stated in

Europe PubMed Central

PubMed publication ID

30 August 2017

1 reference

1 reference

Naishi Li

1 reference

Europe PubMed Central

PubMed publication ID

24529133

reference URL

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24529133%20AND%20SRC:MED&resulttype=core&format=json

retrieved

5 June 2020

Debby P Koonen

series ordinal

1 reference

stated in

Europe PubMed Central

PubMed publication ID

24529133

reference URL

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24529133%20AND%20SRC:MED&resulttype=core&format=json

retrieved

5 June 2020

Jan Albert Kuivenhoven

series ordinal

1 reference

stated in

Europe PubMed Central

PubMed publication ID

24529133

reference URL

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24529133%20AND%20SRC:MED&resulttype=core&format=json

retrieved

5 June 2020

Marten H Hofker

series ordinal

1 reference

stated in

Europe PubMed Central

PubMed publication ID

24529133

reference URL

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24529133%20AND%20SRC:MED&resulttype=core&format=json

retrieved

5 June 2020

publication date

7 January 2014

1 reference

stated in

Europe PubMed Central

PubMed publication ID

30 August 2017

1 reference

Europe PubMed Central

PubMed publication ID

24529133

reference URL

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24529133%20AND%20SRC:MED&resulttype=core&format=json

retrieved

5 June 2020

volume

233

1 reference

stated in

Europe PubMed Central

PubMed publication ID

24529133

reference URL

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24529133%20AND%20SRC:MED&resulttype=core&format=json

retrieved

5 June 2020

issue

1 reference

stated in

Europe PubMed Central

PubMed publication ID

24529133

reference URL

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24529133%20AND%20SRC:MED&resulttype=core&format=json

retrieved

5 June 2020

page(s)

130-138

1 reference

stated in

Europe PubMed Central

PubMed publication ID

24529133

reference URL

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24529133%20AND%20SRC:MED&resulttype=core&format=json

retrieved

5 June 2020

cites work

Mendelian randomization studies do not support a role for raised circulating triglyceride levels influencing type 2 diabetes, glucose levels, or insulin resistance

1 reference

27 August 2024

https://opencitations.net/index/api/v1/references/10.1016/J.ATHEROSCLEROSIS.2013.12.013

The long-term effect of lifestyle interventions to prevent diabetes in the China Da Qing Diabetes Prevention Study: a 20-year follow-up study

1 reference

27 August 2024

https://opencitations.net/index/api/v1/references/10.1016/J.ATHEROSCLEROSIS.2013.12.013

Impaired glucose tolerance and its relationship to ECG-indicated coronary heart disease and risk factors among Chinese. Da Qing IGT and diabetes study

1 reference

27 August 2024

https://opencitations.net/index/api/v1/references/10.1016/J.ATHEROSCLEROSIS.2013.12.013

Effect of torcetrapib on glucose, insulin, and hemoglobin A1c in subjects in the Investigation of Lipid Level Management to Understand its Impact in Atherosclerotic Events (ILLUMINATE) trial

1 reference

27 August 2024

https://opencitations.net/index/api/v1/references/10.1016/J.ATHEROSCLEROSIS.2013.12.013

High-density lipoprotein modulates glucose metabolism in patients with type 2 diabetes mellitus

1 reference

27 August 2024

https://opencitations.net/index/api/v1/references/10.1016/J.ATHEROSCLEROSIS.2013.12.013

Triglyceride-induced diabetes associated with familial lipoprotein lipase deficiency

1 reference

27 August 2024

https://opencitations.net/index/api/v1/references/10.1016/J.ATHEROSCLEROSIS.2013.12.013

Efficacy of long-term ezetimibe therapy in patients with nonalcoholic fatty liver disease

1 reference

27 August 2024

https://opencitations.net/index/api/v1/references/10.1016/J.ATHEROSCLEROSIS.2013.12.013

Pravastatin and the development of diabetes mellitus: evidence for a protective treatment effect in the West of Scotland Coronary Prevention Study

1 reference

27 August 2024

https://opencitations.net/index/api/v1/references/10.1016/J.ATHEROSCLEROSIS.2013.12.013

The emerging role of HDL in glucose metabolism

1 reference

27 August 2024

https://opencitations.net/index/api/v1/references/10.1016/J.ATHEROSCLEROSIS.2013.12.013

Mendelian randomization: prospects, potentials, and limitations

1 reference

27 August 2024

https://opencitations.net/index/api/v1/references/10.1016/J.ATHEROSCLEROSIS.2013.12.013

Differential diagnosis of familial high density lipoprotein deficiency syndromes

1 reference

27 August 2024

https://opencitations.net/index/api/v1/references/10.1016/J.ATHEROSCLEROSIS.2013.12.013

Colesevelam improves oral but not intravenous glucose tolerance by a mechanism independent of insulin sensitivity and β-cell function

1 reference

27 August 2024

https://opencitations.net/index/api/v1/references/10.1016/J.ATHEROSCLEROSIS.2013.12.013

The effect of a bile acid sequestrant on glucose metabolism in subjects with type 2 diabetes

1 reference

27 August 2024

https://opencitations.net/index/api/v1/references/10.1016/J.ATHEROSCLEROSIS.2013.12.013

Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance

1 reference

27 August 2024

https://opencitations.net/index/api/v1/references/10.1016/J.ATHEROSCLEROSIS.2013.12.013

Carriers of loss-of-function mutations in ABCA1 display pancreatic beta-cell dysfunction

1 reference

27 August 2024

https://opencitations.net/index/api/v1/references/10.1016/J.ATHEROSCLEROSIS.2013.12.013

Cholesterol in islet dysfunction and type 2 diabetes

1 reference

27 August 2024

https://opencitations.net/index/api/v1/references/10.1016/J.ATHEROSCLEROSIS.2013.12.013

Low- and high-density lipoproteins modulate function, apoptosis, and proliferation of primary human and murine pancreatic beta-cells

1 reference

27 August 2024

https://opencitations.net/index/api/v1/references/10.1016/J.ATHEROSCLEROSIS.2013.12.013

Place of pitavastatin in the statin armamentarium: promising evidence for a role in diabetes mellitus

1 reference

27 August 2024

https://opencitations.net/index/api/v1/references/10.1016/J.ATHEROSCLEROSIS.2013.12.013

Ezetimibe ameliorates atherosclerotic and inflammatory markers, atherogenic lipid profiles, insulin sensitivity, and liver dysfunction in Japanese patients with hypercholesterolemia

1 reference

27 August 2024

https://opencitations.net/index/api/v1/references/10.1016/J.ATHEROSCLEROSIS.2013.12.013

Large-scale gene-centric meta-analysis across 32 studies identifies multiple lipid loci

1 reference

27 August 2024

https://opencitations.net/index/api/v1/references/10.1016/J.ATHEROSCLEROSIS.2013.12.013

Preferential uptake of dietary Fatty acids in adipose tissue and muscle in the postprandial period

1 reference

27 August 2024

https://opencitations.net/index/api/v1/references/10.1016/J.ATHEROSCLEROSIS.2013.12.013

The angiopoietin-like protein 3: a hepatokine with expanding role in metabolism

1 reference

27 August 2024

https://opencitations.net/index/api/v1/references/10.1016/J.ATHEROSCLEROSIS.2013.12.013

Lowering of plasma glucose concentrations with bezafibrate in patients with moderately controlled NIDDM

1 reference

27 August 2024

https://opencitations.net/index/api/v1/references/10.1016/J.ATHEROSCLEROSIS.2013.12.013

Reduction in the Incidence of Type 2 Diabetes with Lifestyle Intervention or Metformin

1 reference

27 August 2024

https://opencitations.net/index/api/v1/references/10.1016/J.ATHEROSCLEROSIS.2013.12.013

Effect of fenofibrate and niacin on intrahepatic triglyceride content, very low-density lipoprotein kinetics, and insulin action in obese subjects with nonalcoholic fatty liver disease

1 reference

27 August 2024

https://opencitations.net/index/api/v1/references/10.1016/J.ATHEROSCLEROSIS.2013.12.013

Association of Taq 1B CETP polymorphism with insulin and HOMA levels in the population of the Canary Islands

1 reference

27 August 2024

https://opencitations.net/index/api/v1/references/10.1016/J.ATHEROSCLEROSIS.2013.12.013

Prediction of incident diabetes mellitus in middle-aged adults: the Framingham Offspring Study

1 reference

27 August 2024

https://opencitations.net/index/api/v1/references/10.1016/J.ATHEROSCLEROSIS.2013.12.013

Novel biological functions of high-density lipoprotein cholesterol

1 reference

27 August 2024

https://opencitations.net/index/api/v1/references/10.1016/J.ATHEROSCLEROSIS.2013.12.013

Lipotoxicity in the pathogenesis of obesity-dependent NIDDM. Genetic and clinical implications.

1 reference

27 August 2024

https://opencitations.net/index/api/v1/references/10.1016/J.ATHEROSCLEROSIS.2013.12.013

Insulin sensitivity is impaired in heterozygous carriers of lipoprotein lipase deficiency

1 reference

27 August 2024

https://opencitations.net/index/api/v1/references/10.1016/J.ATHEROSCLEROSIS.2013.12.013

Phenomics, lipodystrophy, and the metabolic syndrome

1 reference

27 August 2024

https://opencitations.net/index/api/v1/references/10.1016/J.ATHEROSCLEROSIS.2013.12.013

Lipoprotein lipase is a gene for insulin resistance in Mexican Americans

1 reference

27 August 2024

https://opencitations.net/index/api/v1/references/10.1016/J.ATHEROSCLEROSIS.2013.12.013

1 reference

27 August 2024

https://opencitations.net/index/api/v1/references/10.1016/J.ATHEROSCLEROSIS.2013.12.013

Colesevelam HCl reduces LDL particle number and increases LDL size in hypercholesterolemia

1 reference

27 August 2024

https://opencitations.net/index/api/v1/references/10.1016/J.ATHEROSCLEROSIS.2013.12.013

Long-Term Predictors of Insulin Resistance: Role of lifestyle and metabolic factors in middle-aged men

1 reference

27 August 2024

https://opencitations.net/index/api/v1/references/10.1016/J.ATHEROSCLEROSIS.2013.12.013

Effects of peroxisome proliferator-activated receptor (PPAR)-alpha and PPAR-gamma agonists on glucose and lipid metabolism in patients with type 2 diabetes mellitus

1 reference

27 August 2024

https://opencitations.net/index/api/v1/references/10.1016/J.ATHEROSCLEROSIS.2013.12.013

Liver fat and insulin resistance are independently associated with the -514C>T polymorphism of the hepatic lipase gene

1 reference

27 August 2024

https://opencitations.net/index/api/v1/references/10.1016/J.ATHEROSCLEROSIS.2013.12.013

Epidemiology of type 2 diabetes and cardiovascular disease: translation from population to prevention: the Kelly West award lecture 2009.

1 reference

27 August 2024

https://opencitations.net/index/api/v1/references/10.1016/J.ATHEROSCLEROSIS.2013.12.013

Frail HDLs and stiff arteries in type 2 diabetes in juveniles

1 reference

27 August 2024

https://opencitations.net/index/api/v1/references/10.1016/J.ATHEROSCLEROSIS.2013.12.013

Cellular cholesterol trafficking and compartmentalization

1 reference

27 August 2024

https://opencitations.net/index/api/v1/references/10.1016/J.ATHEROSCLEROSIS.2013.12.013

APOC3 null mutation affects lipoprotein profile APOC3 deficiency: from mice to man

1 reference

27 August 2024

https://opencitations.net/index/api/v1/references/10.1016/J.ATHEROSCLEROSIS.2013.12.013

Sustained reduction in the incidence of type 2 diabetes by lifestyle intervention: follow-up of the Finnish Diabetes Prevention Study

1 reference

27 August 2024

https://opencitations.net/index/api/v1/references/10.1016/J.ATHEROSCLEROSIS.2013.12.013

Long-term effect of bezafibrate on pancreatic beta-cell function and insulin resistance in patients with diabetes

1 reference

27 August 2024

https://opencitations.net/index/api/v1/references/10.1016/J.ATHEROSCLEROSIS.2013.12.013

Genetic and physiological insights into the metabolic syndrome

1 reference

27 August 2024

https://opencitations.net/index/api/v1/references/10.1016/J.ATHEROSCLEROSIS.2013.12.013

Role of Insulin in Endogenous Hypertriglyceridemia*

1 reference

27 August 2024

https://opencitations.net/index/api/v1/references/10.1016/J.ATHEROSCLEROSIS.2013.12.013

Interactions of Obesity, and Glucose and Insulin Levels in Hypertriglyceridemia

1 reference

27 August 2024

https://opencitations.net/index/api/v1/references/10.1016/J.ATHEROSCLEROSIS.2013.12.013

Lipodystrophy: lessons in lipid and energy metabolism

1 reference

27 August 2024

https://opencitations.net/index/api/v1/references/10.1016/J.ATHEROSCLEROSIS.2013.12.013

Colesevelam for type 2 diabetes mellitus

1 reference

27 August 2024

https://opencitations.net/index/api/v1/references/10.1016/J.ATHEROSCLEROSIS.2013.12.013

Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials

1 reference

27 August 2024

https://opencitations.net/index/api/v1/references/10.1016/J.ATHEROSCLEROSIS.2013.12.013

Modulating LDL cholesterol and glucose in patients with type 2 diabetes mellitus: targeting the bile acid pathway

1 reference

27 August 2024

https://opencitations.net/index/api/v1/references/10.1016/J.ATHEROSCLEROSIS.2013.12.013

A ceramide-centric view of insulin resistance

1 reference

27 August 2024

https://opencitations.net/index/api/v1/references/10.1016/J.ATHEROSCLEROSIS.2013.12.013

Small high-density lipoprotein (HDL) subclasses are increased with decreased activity of HDL-associated phospholipase A₂ in subjects with prediabetes.

1 reference

27 August 2024

https://opencitations.net/index/api/v1/references/10.1016/J.ATHEROSCLEROSIS.2013.12.013

G-250A substitution in promoter of hepatic lipase gene is associated with dyslipidemia and insulin resistance in healthy control subjects and in members of families with familial combined hyperlipidemia

1 reference

27 August 2024

https://opencitations.net/index/api/v1/references/10.1016/J.ATHEROSCLEROSIS.2013.12.013

Inflammation and lipid signaling in the etiology of insulin resistance

1 reference

27 August 2024

https://opencitations.net/index/api/v1/references/10.1016/J.ATHEROSCLEROSIS.2013.12.013

Banting lecture 1988. Role of insulin resistance in human disease

1 reference

27 August 2024

https://opencitations.net/index/api/v1/references/10.1016/J.ATHEROSCLEROSIS.2013.12.013

Differing effect of statins on insulin sensitivity in non-diabetics: a systematic review and meta-analysis

1 reference

27 August 2024

https://opencitations.net/index/api/v1/references/10.1016/J.ATHEROSCLEROSIS.2013.12.013

Peroxisome proliferator-activated receptor ligand bezafibrate for prevention of type 2 diabetes mellitus in patients with coronary artery disease

1 reference

27 August 2024

https://opencitations.net/index/api/v1/references/10.1016/J.ATHEROSCLEROSIS.2013.12.013

Gluttony, sloth and the metabolic syndrome: a roadmap to lipotoxicity

1 reference

27 August 2024

https://opencitations.net/index/api/v1/references/10.1016/J.ATHEROSCLEROSIS.2013.12.013

Beta-cell lipotoxicity in the pathogenesis of non-insulin-dependent diabetes mellitus of obese rats: impairment in adipocyte-beta-cell relationships

1 reference

27 August 2024

https://opencitations.net/index/api/v1/references/10.1016/J.ATHEROSCLEROSIS.2013.12.013

Genetic predisposition to dyslipidemia and type 2 diabetes risk in two prospective cohorts

1 reference

27 August 2024

https://opencitations.net/index/api/v1/references/10.1016/J.ATHEROSCLEROSIS.2013.12.013

The worldwide epidemiology of type 2 diabetes mellitus--present and future perspectives

1 reference

27 August 2024

https://opencitations.net/index/api/v1/references/10.1016/J.ATHEROSCLEROSIS.2013.12.013

Effect of bile acid sequestrants on glucose metabolism, hepatic de novo lipogenesis, and cholesterol and bile acid kinetics in type 2 diabetes: a randomised controlled study

1 reference

27 August 2024

https://opencitations.net/index/api/v1/references/10.1016/J.ATHEROSCLEROSIS.2013.12.013

10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study

1 reference

27 August 2024

https://opencitations.net/index/api/v1/references/10.1016/J.ATHEROSCLEROSIS.2013.12.013

Linking disease associations with regulatory information in the human genome

1 reference

27 August 2024

https://opencitations.net/index/api/v1/references/10.1016/J.ATHEROSCLEROSIS.2013.12.013

The triglyceride-to-HDL cholesterol ratio: association with insulin resistance in obese youths of different ethnic backgrounds

1 reference

27 August 2024

https://opencitations.net/index/api/v1/references/10.1016/J.ATHEROSCLEROSIS.2013.12.013

Type 2 diabetes risk in persons with dysglycemia: the Framingham Offspring Study

1 reference

27 August 2024

https://opencitations.net/index/api/v1/references/10.1016/J.ATHEROSCLEROSIS.2013.12.013

Attenuation of progression of insulin resistance in patients with coronary artery disease by bezafibrate

1 reference

27 August 2024

https://opencitations.net/index/api/v1/references/10.1016/J.ATHEROSCLEROSIS.2013.12.013

Mechanisms for insulin resistance: common threads and missing links

1 reference

27 August 2024

https://opencitations.net/index/api/v1/references/10.1016/J.ATHEROSCLEROSIS.2013.12.013

Insulin resistance and coronary heart disease in nondiabetic individuals

1 reference

27 August 2024

https://opencitations.net/index/api/v1/references/10.1016/J.ATHEROSCLEROSIS.2013.12.013

Apolipoprotein E isoforms, serum cholesterol, and cancer.

1 reference

27 August 2024

https://opencitations.net/index/api/v1/references/10.1016/J.ATHEROSCLEROSIS.2013.12.013

Biological, clinical and population relevance of 95 loci for blood lipids

1 reference

27 August 2024

https://opencitations.net/index/api/v1/references/10.1016/J.ATHEROSCLEROSIS.2013.12.013

The metabolic syndrome

1 reference

27 August 2024

https://opencitations.net/index/api/v1/references/10.1016/J.ATHEROSCLEROSIS.2013.12.013

Haplotypes in the lipoprotein lipase gene influence fasting insulin and discovery of a new risk haplotype

1 reference

27 August 2024

https://opencitations.net/index/api/v1/references/10.1016/J.ATHEROSCLEROSIS.2013.12.013

‘Mendelian randomization’: can genetic epidemiology contribute to understanding environmental determinants of disease?*

1 reference

27 August 2024

https://opencitations.net/index/api/v1/references/10.1016/J.ATHEROSCLEROSIS.2013.12.013

Angptl3 deficiency is associated with increased insulin sensitivity, lipoprotein lipase activity, and decreased serum free fatty acids

1 reference

27 August 2024

https://opencitations.net/index/api/v1/references/10.1016/J.ATHEROSCLEROSIS.2013.12.013

The -514 C/T polymorphism in the hepatic lipase gene promoter is associated with insulin sensitivity in a healthy young population.

1 reference

27 August 2024

https://opencitations.net/index/api/v1/references/10.1016/J.ATHEROSCLEROSIS.2013.12.013

Pitavastatin: an overview

1 reference

27 August 2024

https://opencitations.net/index/api/v1/references/10.1016/J.ATHEROSCLEROSIS.2013.12.013

Possible contributions of lipoproteins and cholesterol to the pathogenesis of diabetes mellitus type 2

1 reference

27 August 2024

https://opencitations.net/index/api/v1/references/10.1016/J.ATHEROSCLEROSIS.2013.12.013

Apolipoprotein C3 gene variants in nonalcoholic fatty liver disease

1 reference

27 August 2024

https://opencitations.net/index/api/v1/references/10.1016/J.ATHEROSCLEROSIS.2013.12.013

Muscle insulin resistance: a case of fat overconsumption, not mitochondrial dysfunction

1 reference

27 August 2024

https://opencitations.net/index/api/v1/references/10.1016/J.ATHEROSCLEROSIS.2013.12.013

Determinants of new-onset diabetes among 19,257 hypertensive patients randomized in the Anglo-Scandinavian Cardiac Outcomes Trial--Blood Pressure Lowering Arm and the relative influence of antihypertensive medication

1 reference

27 August 2024

https://opencitations.net/index/api/v1/references/10.1016/J.ATHEROSCLEROSIS.2013.12.013

Identifiers

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q38188133&oldid=2237761347"

Are hypertriglyceridemia and low HDL causal factors in the development of insulin resistance? (Q38188133)

Statements

Identifiers

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Navigation menu

Search